Ann: Positive preliminary results from ATL1102 DMD Phase II trial, page-4

"As an indicator of ATL1102’s suggestive positive effects on disease progression (being the type of endpoints required for future product registration) in the current trial, ANP has previously referenced the Ricotti et al 2016 publication that evaluated disease progression in non-ambulant boys over a 6 month period, where a significant mean reduction in upper body muscle strength of the subjects was observed. By comparison, the data on the first 6 patients completing dosing in the ATL1102 trial, shows a distinct improvement in these strength parameters over the losses noted in the Ricotti publication (refer Appendix A).